Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress

Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma On Track to Report Top-Line Data from STORM and STOMP Studies in Relapsed/Refractory Multiple Myeloma and...
August 03, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm to Present at Upcoming Investor Conferences

NEWTON, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will...
July 28, 2016 08:00 ET | Source: Karyopharm Therapeutics

Karyopharm to Report Second Quarter 2016 Financial Results on August 4, 2016

NEWTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2016...
July 27, 2016 16:05 ET | Source: Karyopharm Therapeutics

Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting

- Oral Presentation Describing Efficacy of Selinexor in Gynecological Cancers - - Posters Highlighting Predictive Biomarkers of Selinexor Activity in Preclinical Models of Gynecological and...
July 27, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published in Journal of Clinical Oncology

Data Provide Early Evidence of Anticancer Activity in Advanced Sarcoma and Inform Recommended Phase 2 Dose Company Also Announces Orphan Drug Designation Granted by FDA for Selinexor in Soft Tissue...
July 06, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

NEWTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
June 22, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274

NEWTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1...
June 16, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Outlines Key Selinexor Clinical Development Achievements

- Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma - - Patient Dosing Underway in Phase 1b Clinical Trial of Selinexor in Combination with Chemotherapeutic, Targeted and...
June 15, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm to Present at the 2016 JMP Securities Life Science Conference

NEWTON, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
June 10, 2016 07:30 ET | Source: Karyopharm Therapeutics

Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting

- Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma - - Preclinical Data for...